PATENT CLAIM ANALYSIS

Application Number: 16068208
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "263320"]

Abstract:
The present invention relates to the field of virology. More specifically, the present invention provides methods and CN compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

Claim (Index 7):
The pharmaceutical composition of  claim 1 , wherein emetine is present at about 1/10 to about 1/100 of the normal dosage for amebiasis.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 95.0
- Lexical Diversity: 1.80645
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14678128', '13887244', '12672491', '15361150', '14394973']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7430509946243736
- 35 USC 102 Novelty (BERT): 0.5294928339848766
- Combined Prediction Score: 0.721695178560424
- Mean Citation Score: 241.916668
- Max Citation Score: 285.2102
- Similarity Product: 163.0821195196986

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test